New developments in the management of diffuse large B-cell lymphoma

References

• Percy C, O’Conor G, Reis LG, Jaffe ES. Non-Hodgkin’s lymphomas: application of the International Classification of Disease for Oncology (ICD-O) to the working formulation. Cancer. 1984;54:1435–8.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al.. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008.
   Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al.. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med. 2002;346:235–42.
   PubMed Web of Science ®Google Scholar
• Feugier P, van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, et al.. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomas de l’Adulte. J Clin Oncol. 2005;23:4117–26.
   PubMed Web of Science ®Google Scholar
• Coffier B, Thieblemont C, van den Neste E, Lepeu G, Plantier I, Castaigne S, et al.. Long-term outcome of patients in the LNH-98·5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’Etudes des Lymphomes de l’Adulte. Blood. 2010;116:2040–5.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Weller EA, Morrison VA, Gascoyne RD, Cassileth PA, Cohn JB, et al.. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121–7.
   PubMed Web of Science ®Google Scholar
• Pfreudschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al.. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large B-cell lymphoma: a randomized study of the MabThera International Trial (MinT) Group. Lancet Oncol. 2006;7:379–91.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Kuhnt E, Trumper L, Osterborg A, Trneny M, Shepherd L, et al.. Randomized intergroup trial of first line treatment for young low-risk patients (<61 years) with diffuse large B-cell lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab-6-year follow-up of the Mint study of the Mabthera International Trial (Mint) Group. Blood. 2010;116:55a.
   Web of Science ®Google Scholar
• Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al.. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23:5027–33.
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al.. Six versus eight cycles of biweekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+B-cell lymphomas: a randomized controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105–16.
   PubMed Web of Science ®Google Scholar
• Pfreunshuh M, Ziepert M, Reiser M, Poeschel V, Wilhelm S, Gaska T, et al.. The role of radiotherapy to bulky disease in the rituximab era: results from two prospective trials of the German High-Grade Non-Hodgkin-Lymphoma Study Group for elderly in diffuse large B-cell lymphoma. Blood. 2008;112:219a.
   PubMed Web of Science ®Google Scholar
• Halaas JH, Moskowitz CH, Horwitz S, Portlock C, Noy A, Straus D, et al.. R-CHOP-14 in patients with diffuse large B-cell lymphoma: feasibility and preliminary efficacy. Leuk Lymphoma. 2005;46:541–7.
   PubMed Web of Science ®Google Scholar
• Brusamolio E, Rusinoi C, Montalbetti L, Gargantini L, Uziel L, Pinotti G, et al.. Dose-dense R-CHOP-14 supported by pegfilgrastrim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity. Haematologica. 2006;91:496–502.
   PubMed Web of Science ®Google Scholar
• Delarue R, Tilly H, Salles G, Gisselbrecht C, Mounier N, Fournier M, et al.. R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma: results of the LNH03-6B study. Blood. 2009;114:169a.
   Web of Science ®Google Scholar
• Cunningham D, Smith P, Mouncey W, Qian W, Jack AS, Pocock C, et al.. R-CHOP14 versus R-CHOP21: result of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell lymphoma. J Clin Oncol. 2011;29:504s.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Nickelsen M, Ziepert M, Haenel P, Borchmann C, Schmidt A, et al.. Aggressive chemotherapy (CHOEP-14) and rituximab for young high-risk patients with aggressive B-cell lymphoma: results of the MegaCHOEP trial of the German High-Grade Lymphoma Study Group (DSHNHL). Blood. 2009;114:168a.
   Web of Science ®Google Scholar
• Recher C, Coffier B, Haioun C, Mounier N, Emile JF, Ranta D, et al.. A prospective randomized study comparing dose intensive immunochemotherapy with R-ACVBP vs. standard R-CHOP in younger patients with diffuse large B-cell lymphoma: Groupe d’Etude Des Lymphomes De l’Adulte (GELA) study LNH03-2B. Blood. 2010;116:53–4a.
   Web of Science ®Google Scholar
• Philip T, Armitage JO, Spitzer G, Chauvin F, Jagannath S, Cahn JY, et al.. High dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate or high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1987;316:1493–8.
   PubMed Web of Science ®Google Scholar
• Applebaum FR. Hematologic cell transplantation for non-Hodgkin lymphoma: yesterday, today, and tomorrow. J Clin Oncol. 2008:26:2927–9.
   PubMed Web of Science ®Google Scholar
• McCarthy PL, Hahn T, Hassebroek A, Klein JP, Rizzo JD, Parsons S, et al.. Significant improvement in overall survival in patients who underwent autologous hematopoietic cell transplant in the US and Canada between 1994 and 2005. Blood. 2010;116:990a.
   Web of Science ®Google Scholar
• Gisselbrecht C, Glass B, Mounier N, Singh Gill D, Linch DC, Trneny M, et al.. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184–90.
   PubMed Web of Science ®Google Scholar
• Thieblemont C, Briere J, Mounier N, Voelker HU, Cuccuini W, Hirchaud E, et al.. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol. 2011;29:4079–87.
   PubMed Web of Science ®Google Scholar
• Krishan A, Palmer J, Nademanee A, Tsai NC, Simpson JR, Nademanee A, et al.. Comparative analysis of autologous hematopoietic cell transplantation with radioimmuntherapy (RIT) based conditioning versus total body irradiation (TBI) for high-risk diffuse large B-cell lymphoma (DLBCL): toxicity and efficacy. Blood. 2010;116:18a.
   Web of Science ®Google Scholar
• Hitz F, Moccia JM, Gasgoyne RD, Hoskins P, Moccia AA, Savage KJ, et al.. Outcome of patients with chemotherapy refractory and early progressive diffuse large B-cell lymphoma after R-CHOP. Blood. 2010;116:731a.
   PubMed Web of Science ®Google Scholar
• Stiff PJ, Unger JM, Cook J, Constine LS, Couban S, Shea TC, et al.. Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP±R for eight cycles to CHOP±R for six cycles followed by autotransplant for patients with high-intermediate (H-int) or high IPI grade diffuse aggressive non-Hodgkin lymphoma (NHL). J Clin Oncol. 2011;29:504s.
   PubMedGoogle Scholar
• Micallef IN, Kahl BS, Maurer MJ, Gayko U, Cesano A, Ansell SM, et al.. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Cancer. 2006;107:2826–32.
   PubMed Web of Science ®Google Scholar
• Micallef IN, Maurer MJ, Wiseman GA, Nikcevich DA, Kurtin PJ, Cannon MW, et al.. Epratuzumab with rituxiab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood. 2011;118:4053–61.
   PubMed Web of Science ®Google Scholar
• Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, et al.. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center markers. J Clin Oncol. 2008;26:2717–24.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, et al.. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113:6069–76.
   PubMed Web of Science ®Google Scholar
• Chanan-Khan AA, Cheson BD. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol. 2008;26:1544–52.
   PubMed Web of Science ®Google Scholar
• Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, et al.. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2008;26:4952–7.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, et al.. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma. Ann Oncol. 2011;22:1622–77.
   PubMed Web of Science ®Google Scholar
• Nowakowski GS, Laplant B, Habermann TM, Rivera CE, Macon WR, Inwards DJ, et al.. Lenalidomide can be safely combined with R-CHOP (R2CHOP) in the initial chemotherapy for aggressive B-cell lymphomas: phase I study. Leukemia. 2011;25:1977–81.
   Web of Science ®Google Scholar
• Freidberg JW, Unger JM, Burack RB, W. Gopal AK, LeBlanc ML, Ajay K, et al.. R-CHOP with Iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): Southwest Oncology Group Protocol S0433. Blood. 2010;116:260a.
   Web of Science ®Google Scholar
• Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, et al.. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2007;25:1741–6.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Tang H, Micallef IN, Ansell SM, Link BK, Inwards DJ, et al.. Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas. Blood. 2011;118:4882–9.
   PubMed Web of Science ®Google Scholar
• Witzig TE, Reeder CB, LaPlant BR, Gupta M, Johnston PB, Micallef IN, et al.. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia. 2011;25:341–7.
   PubMed Web of Science ®Google Scholar
• Kumar S, Porrata LF, Ansell SM, Colgan JP, LaPlant B, Gertz MA, et al.. Phase I trial of sorafenib and everolimus in patients with lymphoma or multiple myeloma. Blood;116:1155a.
   Google Scholar
• Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, et al.. Inhibition of Syk with fostamainib disodium has significant clinical activity in non-Hodgkin’s lymphoma and chronic lymphocytic leukemia. Blood. 2010;115:2578–85.
   PubMed Web of Science ®Google Scholar
• Lim SH, Beers SA, French RR, Johnson PW, Glennie MJ, Cragg MS. Anti-CD20 monoclonal antibodies: historical and future perspectives. Haematologica. 2010;95:135–43.
   PubMed Web of Science ®Google Scholar
• Cartron G, Thieblemont C, Solal-Celegny P, Morshchhauser F, Haloun C, Bouabdallah R, et al.. Promising efficacy with the new anti-CD20 antibody GA101 in heavily pre-treated NHL patients — first results from a phase II study in relapsed/refractory DLBCL and MCL. Blood. 2010;116:1185a.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Bosly A, Wu KL, Verhoef G, Koen VE, Martinelli G, et al.. Ofatumomab montherapy for treatment of patients with relapsed/progressive diffuse large B-cell lymphoma: results from a phase multicenter II study. Blood. 2010;116:1613a.
   PubMed Web of Science ®Google Scholar
• Negrea GO, Elstrom R, Allen SL, Rai KR, Abbasi RM, Farber CM, et al.. Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active inpatients with indolent non-Hodgkin’s lymphoma. Haematologica. 2011;96:567–73.
   PubMed Web of Science ®Google Scholar
• Fowler N, Sharman JP, Smith SM, Boyd T, Grant B, Kolibaba KS, et al.. The Btk inhibitor, PCI-32765, induces durable responses with minimal toxicity in patients with relapsed/refractory B-cell malignancies: results from a phase I trial. Blood. 2010;116:425a
   Web of Science ®Google Scholar
• Lohr J, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, et al.. Discovery and prioritization of somatic mutations in diffuse large B cell lymphoma (DLBCL) by whole-exome sequencing. PNAS. 2012. February, [Epub ahead of print]; doi/10.1073/pnas.1121343109.
   Google Scholar